Atopic Dermatitis
1,079
121
172
640
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
238 trials with published results (22%)
Research Maturity
640 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.4%
80 terminated out of 1079 trials
88.9%
+2.4% vs benchmark
23%
244 trials in Phase 3/4
37%
238 of 640 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 640 completed trials
Clinical Trials (1079)
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Phase I Clinical Trial to Evaluate CU-10101 Unguent
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
The Impact of Dietary Salt on the Severity of Eczema
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Cardamom and Topical Roseomonas in Atopic Dermatitis
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
A Phase Ib/II Study of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis